Loading... Please wait...

Blog - ADC

CellMosaic to exhibit at the AACR annual meeting 2019

Posted

Come visit us at Booth 4622 close to the entrance of the Exhibition Hall, meet our experts to find out about more recent developments in bioconjugation at CellMosaic and learn about how our bioconjugation solutions will help you in your research and drug development. Featured topics include CellMosaic’s:

  • Personalized antibody-drug conjugation kits to help in ADC development
  • Proprietary super-hydrophilic AqueaTether™ (AqT™) linkers for drug conjugation, delivery, and diagnostic research
  • AqueaTether™ linker-based conjugation kits and products
  • Other personalized conjugation kits
  • Custom bioconjugation services


Date: March 29-April 3, 2019

Location: Georgia World Congress Center, Atlanta, Georgia, USA

Exhibit Show Dates and Times:

Sunday, March 31, 1 – 5 pm

Monday, April 1, 9 am – 5 pm

Tuesday, April 2, 9 am – 5 pm

Wednesday, April 3, 9 am – 5 pm 


About CellMosaic, Inc.

CellMosaic, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. Several key technologies are being developed at CellMosaic, including oxLink technologies for studying protein–protein interactions; NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest; super-hydrophilic AqueaTether linkers for clean conjugation of antibody/protein/peptide/oligo with small molecule drugs; biocompatible, biodegradable, mono-dispersed AqueaTether macromolecules for modification of protein/peptide/oligo drugs and preparation of highly loaded small molecule drugs for better delivery; and bioconjugation platform technologies involving screening, labeling/crosslinking, purification, and analysis of any bioconjugate. The company is also actively engaged in serving biological communities by providing custom synthesis of high quality bioconjugate products.

About AqueaTether Therapeutics.

AqueaTether Therapeutics is a division of CellMosaic, created in 2016. AqueaTether™ Therapeutics focuses on the discovery and development of novel hybrid drug entities beyond the conventional drug classes by using AqueaTether ™ (AqT™) conjugation and delivery platform technologies. We work together with our partners to advance their program. For more information regarding AqueaTether-based bioconjugate drugs, please visit our website: www.aqttherapeutics.com

CellMosaic Inc. received Notice of Allowance on AqueaTether™ (AqT™) molecules from the Australian Intellectual Property Office

Woburn, MA, Nov. 1st, 2017 – CellMosaic announced today that the Australian Government IP Office issued a formal Notice of Allowance for a patent on AqueaTether (AqT™) molecules (Application No. 2012284055 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). Upon issuance, the patent will provide intellectual property protection for a broad range of AqT™ molecules constructed from [...]

Read More »